Publications by authors named "Ingel Demedts"

Claim this Profile
I
Impact of the COVID-19 pandemic on lung cancer diagnosis, treatment, mortality, and survival in Belgium: A population-based study.
Hanne Peirelinck, Hanna M Peacock, Geert Silversmit, Thierry Berghmans, Paul De Leyn, Ingel Demedts

Respir Med Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An acquired CCDC6:: gene fusion as resistance mechanism for Osimertinib in exon 21 -mutated non-small cell lung cancer and its successful management with Osimertinib and Selpercatinib: a case report and review of literature.
Maud Lormans, Peter Van Haecke, Ingel Demedts

J Chemother· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer.
Jonas Claus, Dieter De Smet, Joke Breyne, Janusz Wesolowski, Ulrike Himpe, Ingel Demedts

Sci Rep· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis.
Oliver Illini, Felix Carl Saalfeld, Petros Christopoulos, Michaël Duruisseaux, Anders Vikström, Ingel Demedts

Int J Mol Sci· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial.
Luis Paz-Ares, Yasushi Goto, Darren Wan-Teck Lim, Balazs Halmos, Byoung Chul Cho, Ingel Demedts

Lung Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study.
Myung-Ju Ahn, Igor Bondarenko, Ewa Kalinka, Byoung Chul Cho, Shunichi Sugawara, Ingel Demedts

J Thorac Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indirect Costs Due to Lung Cancer-Related Premature Mortality in Four European Countries.
Goran Bencina, Nour Chami, Robert Hughes, Georgie Weston, Carl Baxter, Ingel Demedts

Adv Ther· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NMR-Metabolomics Reveals a Metabolic Shift after Surgical Resection of Non-Small Cell Lung Cancer.
Elien Derveaux, Melvin Geubbelmans, Maarten Criel, Ingel Demedts, Ulrike Himpe

Cancers (Basel)· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment.
Cedric Bosteels, Karel F A Van Damme, Elisabeth De Leeuw, Jozefien Declercq, Bastiaan Maes, Ingel K Demedts

Cell Rep Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the implementation of Value-Based Healthcare with a weekly digital follow-up of lung cancer patients in clinical practice.
Sarah Misplon, Wim Marneffe, Ulrike Himpe, Johan Hellings, Ingel Demedts

Eur J Cancer Care (Engl)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial.
Elisabeth De Leeuw, Karel F A Van Damme, Jozefien Declercq, Cedric Bosteels, Bastiaan Maes, Ingel K Demedts

Respir Res· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.
D Ross Camidge, Teresa Moran, Ingel Demedts, Heidrun Grosch, Kathryn Mileham

Clin Lung Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prospective, multicenter, noninterventional study of decision factors in the first-line treatment of metastatic non-small cell lung cancer.
Anne Sibille, Frederique Bustin, Luciano Carestia, Gaetan Catala, Christophe Compère, Ingel Demedts

Acta Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of an Ultrasensitive NGS-Based Blood Test for the Diagnosis of Early-Stage Lung Cancer: Sensitivity, a Hurdle Still Difficult to Overcome.
Malaïka Van der Linden, Bram Van Gaever, Lennart Raman, Karim Vermaelen, Ingel Demedts

Cancers (Basel)· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
Jozefien Declercq, Karel F A Van Damme, Elisabeth De Leeuw, Bastiaan Maes, Cedric Bosteels, Ingel K Demedts

Lancet Respir Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical implementation of value based healthcare: Impact on outcomes for lung cancer patients.
Ingel Demedts, Ulrike Himpe, Jelle Bossuyt, Geert Anthoons, Hannelore Bode

Lung Cancer· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Which outcomes are most important to measure in patients with COVID-19 and how and when should these be measured? Development of an international standard set of outcomes measures for clinical use in patients with COVID-19: a report of the International Consortium for Health Outcomes Measurement (ICHOM) COVID-19 Working Group.
William H Seligman, Luz Fialho, Nick Sillett, Christina Nielsen, Farhala M Baloch, Ingel K M Demedts

BMJ Open· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lung Cancer in Belgium.
Sebahat Ocak, Kurt Tournoy, Thierry Berghmans, Ingel Demedts, Rodolphe Durieux

J Thorac Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study.
Kristof Cuppens, Liesbet Lodewyckx, Ingel Demedts, Lore Decoster, Benoît Colinet

Drugs Real World Outcomes· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic Performance of Chest CT for SARS-CoV-2 Infection in Individuals with or without COVID-19 Symptoms.
Kristof De Smet, Dieter De Smet, Thomas Ryckaert, Emanuel Laridon, Birgit Heremans, Ingel Demedts

Radiology· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial.
Solange Peters, Sarah Danson, Baktiar Hasan, Urania Dafni, Niels Reinmuth, Ingel Demedts

J Thorac Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma.
Lennart Raman, Malaïka Van der Linden, Kim Van der Eecken, Karim Vermaelen, Ingel Demedts

Genome Med· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer.
Benjamin Besse, Fabrice Barlesi, Ingel Demedts, Jose Fuentes Pradera, Gilles Robinet

Lung Cancer· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azithromycin during Acute Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization (BACE). A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial.
Kristina Vermeersch, Maria Gabrovska, Joseph Aumann, Ingel K Demedts, Jean-Louis Corhay

Am J Respir Crit Care Med· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment failure and hospital readmissions in severe COPD exacerbations treated with azithromycin versus placebo - a post-hoc analysis of the BACE randomized controlled trial.
Kristina Vermeersch, Ann Belmans, Kris Bogaerts, Iwein Gyselinck, Nina Cardinaels, Ingel K Demedts

Respir Res· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis